Sumer, AzizDemir, AliKemik, Ahu SarbayYavuz, AlpaslanSuvak, BurakDulger, Ahmet CumhurKemik, Ozgur2025-05-102025-05-1020170003-469X2239-253X2-s2.0-85018273499https://hdl.handle.net/20.500.14720/17413Kemik, Ozgur/0000-0002-4612-1428; Demir, Ali/0000-0002-9794-1768AIM: Esophageal cancer is one of the most aggressive tumors of the gastrointestinal tract. In this study, we quantified the serum vascular endothelial growth factor-3 (VEGFR-3) expression in patients with esophageal squamous cell carcinoma (ESCC) to evaluate the role of VEGFR-3 in ESCC. MATERIALS AND METHODS: Ninety five patients with ESCC were studied. Pre-therapy and preoperative samples were stored and ELISA was used to designate the concentrations of VEGFR-3. RESULTS: The serum values of VEGFR-3 were significantly higher in patients with ESCC than in healthy donors (p<0.0001). CONCLUSIONS: The results imply a very good sensitivity of VEGFR-3 in ESCC. VEGFR-3 may be a good diagnostic biomarker for ESCC.eninfo:eu-repo/semantics/closedAccessBiomarkerEsccVegfr-3Serum Vascular Endothelial Growth Factor Receptor-3 Levels in Patients With Esophageal Squamous Cell CancerArticle881Q4Q3202528447586WOS:000398426800004